Science Explorer Back to mapMap

Most cited papers from South Texas Accelerated Research Therapeutics

South Texas Accelerated Research Therapeutics

What are the most cited papers from South Texas Accelerated Research Therapeutics?

The most cited paper from South Texas Accelerated Research Therapeutics is "Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer" (Edward B. Garon et al., 2015), with 6,312 citations. Next come "Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma" (3,425) and "Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children" (2,827).

Showing 50 of 60 papers. Every paper with more than 141 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer Edward B. Garon et al. · New England Journal of Medicine Open access 19 Apr 2015 6,312
2 Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Omid Hamid et al. · New England Journal of Medicine Open access 2 Jun 2013 3,425
3 Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children Alexander Edward Dela Cruz Drilon et al. · New England Journal of Medicine Open access 21 Feb 2018 2,827
4 Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Mark E. Davis, Jonathan E. Zuckerman, Chung Hang Jonathan Choi et al. · Nature Open access 21 Mar 2010 2,506
5 Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Caroline Robert et al. · The Lancet 14 Jul 2014 1,779
6 Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study Corey Jay Langer, Shirish M. Gadgeel, Hossein Borghaei et al. · The Lancet Oncology Open access 12 Oct 2016 1,407
7 Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study Edward B. Garon, Matthew D. Hellmann, Naiyer A. Rizvi et al. · Journal of Clinical Oncology Open access 2 Jun 2019 1,210
8 Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma Antoni Ribas et al. · JAMA Open access 19 Apr 2016 1,081
9 Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 Omid Hamid, Caroline Robert, ADIL I. DAUD et al. · Annals of Oncology Open access 29 Jan 2019 961
10 Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors Amita Patnaik et al. · Clinical Cancer Research 14 May 2015 813
11 Efficacy of Selpercatinib in RET -Altered Thyroid Cancers Lori J. Wirth et al. · New England Journal of Medicine Open access 26 Aug 2020 801
12 Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors Amita Patnaik et al. · Cancer Discovery 23 May 2016 773
13 First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers Branimir Ivan Sikic et al. · Journal of Clinical Oncology Open access 27 Feb 2019 605
14 First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors Timothy Anthony Yap, Yan Li, Amita Patnaik et al. · Journal of Clinical Oncology 25 Oct 2011 545
15 Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial Vicky Makker, Drew Warren Rasco, Nicholas J. Vogelzang et al. · The Lancet Oncology Open access 26 Mar 2019 482
16 Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors Matthew Hiram Taylor, Chung‐Han Lee, Vicky Makker et al. · Journal of Clinical Oncology Open access 21 Jan 2020 459
17 The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer Toshio Shimizu, Anthony W. Tolcher, Kyriakos P. Papadopoulos et al. · Clinical Cancer Research 19 Jan 2012 434
18 First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study Ryan Joseph Sullivan et al. · Cancer Discovery 15 Dec 2017 430
19 Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA Jonathan E. Zuckerman, Ismael Gritli, Anthony W. Tolcher et al. · Proceedings of the National Academy of Sciences Open access 21 Jul 2014 425
20 A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer Manuel M. Hidalgo, Elizabeth M. Bruckheimer, N.V. Rajeshkumar et al. · Molecular Cancer Therapeutics Open access 15 Jun 2011 410
21 Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma Vincenzo Mazzaferro, Bassel F. El‐Rayes, Michele Droz Dit Busset et al. · British Journal of Cancer Open access 7 Nov 2018 385
22 Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation Adrian Gerold Sacher et al. · New England Journal of Medicine Open access 23 Aug 2023 317
23 First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1) Sai‐Hong Ignatius Ou, Pasi Antero Janne, Ticiana A.B. Leal et al. · Journal of Clinical Oncology Open access 15 Feb 2022 316
24 Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab Richard Wayne Joseph et al. · Clinical Cancer Research Open access 23 Apr 2018 314
25 Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis Toni K. Choueiri, Todd Michael Bauer, Kyriakos P. Papadopoulos et al. · Nature Medicine Open access 22 Apr 2021 309
26 An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma Yotam Drier, Matthew J. Cotton, Kaylyn E. Williamson et al. · Nature Genetics Open access Feb 2016 303
27 First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆ Jiaxin Niu, Corinne Maurice‐Dror, D.H. Lee et al. · Annals of Oncology Open access 17 Nov 2021 298
28 Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors Anthony W. Tolcher, Wells A. Messersmith, Stanislaw M. Mikulski et al. · Journal of Clinical Oncology Open access 24 Apr 2012 280
29 A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors Shahneen Kaur Sandhu, Kyri P. Papadopoulos, Peter C.C. Fong et al. · Cancer Chemotherapy and Pharmacology 5 Feb 2013 273
30 PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients Aung Naing et al. · Cancer Cell Open access Nov 2018 256
31 Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas Sant P. Chawla, Arthur P. Staddon, Laurence H. Baker et al. · Journal of Clinical Oncology Open access 8 Nov 2011 248
32 First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas Amita Patnaik et al. · Annals of Oncology Open access 26 Sep 2016 241
33 Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial Rina Hui, Edward B. Garon, J.W. Goldman et al. · Annals of Oncology Open access 7 Feb 2017 240
34 Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities David Wesley Craig et al. · Molecular Cancer Therapeutics 20 Nov 2012 226
35 Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study Maeve Aine Lowery et al. · ˜The œLancet. Gastroenterology & hepatology Open access 9 Jul 2019 223
36 MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer Lars D. Engstrom et al. · Cancer Discovery Open access 8 Aug 2023 219
37 First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors Kyriakos P. Papadopoulos, Larry Gluck, Lainie P. Martin et al. · Clinical Cancer Research 27 Jun 2017 217
38 Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors Robert H. Vonderheide, Jennifer M. Burg, Rosemarie Mick et al. · OncoImmunology Open access 2013 205
39 Recent Developments in Amber Biomolecular Simulations David Andrew Case et al. · Journal of Chemical Information and Modeling Open access 29 Jul 2025 204
40 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer Hossein Borghaei, Corey Jay Langer, Shirish M. Gadgeel et al. · Journal of Thoracic Oncology Open access 20 Aug 2018 200
41 Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study Funda Meric‐Bernstam et al. · The Lancet Oncology Open access 15 Nov 2022 198
42 Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors L. Rhoda Molife, Yan Li, Joanna Vitfell-Rasmussen et al. · Journal of Hematology & Oncology Open access 3 Jan 2014 192
43 Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study Chung‐Han Lee et al. · The Lancet Oncology Open access 15 Jun 2021 189
44 Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC Mark Magdi Awad, Shirish M. Gadgeel, Hossein Borghaei et al. · Journal of Thoracic Oncology Open access 15 Oct 2020 187
45 Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation James Chih‐Hsin Yang, Shirish M. Gadgeel, Lecia VanDam Sequist et al. · Journal of Thoracic Oncology Open access 4 Dec 2018 185
46 Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study Natasha B. Leighl, Matthew David Hellmann, Rina Hui et al. · The Lancet Respiratory Medicine 12 Mar 2019 182
47 Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study Aditya Bardia, Ian E. Krop, Takahiro Kogawa et al. · Journal of Clinical Oncology Open access 23 Apr 2024 178
48 Antibody drug conjugates: lessons from 20 years of clinical experience Anthony W. Tolcher · Annals of Oncology Open access 13 Oct 2016 171
49 Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody James J. Harding, Víctor Moreno, Yung‐Jue Bang et al. · Clinical Cancer Research Open access 29 Jan 2021 165
50 Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma William D. Tap, Victor Manuel Villalobos, Gregory Michael Cote et al. · Journal of Clinical Oncology Open access 25 Mar 2020 165

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.